Microarray analysis of the leukocyte global gene expression profile following lithium treatment

ABSTRACT: To further development of our gene expression approach to lithium pharmacodynamics, we have employed whole genome microarray expression profiling as a discovery platform to identify genes with the potential to distinguish lithium pharmacodynamics across an exposure range relevant for medical decision-making in lithium therapy. 8 healthy male subjects participated in this study. Lithium was prescribed for 2 weeks, enough to reach a therapeutic serum concentration (0.6-1.0mM). Leukocyte counts and serum lithium concentrations were determined at baseline (before medication), after 1 week and 2 weeks medication and post-2-weeks (2 weeks after stopping medication). Gene expression profiling was performed at each time point using Agilent G4112F Whole Human Genome arrays containing approximately

ORGANISM(S): Homo sapiens

SUBMITTER: Junichi Iga 

PROVIDER: E-GEOD-44987 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress